Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVE PPH: misoprostol plus oxytocin versus oxytocin alone for prevention of postpartum hemorrhage in Ethiopia
PACTR202503857461324Phase 4Not yet recruiting
- Sponsor
- Ethiopian Society of Obstetricians and Gynecologists
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in postpartum hemorrhage (PPH) comparing Misoprostol plus oxytocin with Oxytocin alone (2 arms). Primary endpoint: Occurrence of primary postpartum hemorrhage. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
misoprostoloxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on PACTR202503857461324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202503857461324.